VIALE, GIUSEPPE

VIALE, GIUSEPPE  

Dipartimento di Oncologia ed Emato-Oncologia  

Mostra records
Risultati 1 - 20 di 623 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 2026 Marra, AntonioMorganti, StefaniaViale, GiuliaZagami, PaolaBuccimazza, GiorgioVenetis, KonstantinosMazzarella, LucaViale, GiuseppeFusco, NicolaCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs 2025 Cursano, GiuliaVenetis, KonstantinosFrascarelli, ChiaraDe Camilli, ElisaCriscitiello, CarmenCurigliano, GiuseppeViale, GiuseppeGuerini-Rocco, ElenaFusco, Nicola + Article (author) -
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 2025 Venetis, KonstantinosCursano, GiuliaGiachetti, Pier Paolo Maria BertonConcardi, AlbertoDe Camilli, ElisaD'Ercole, MariannaFrascarelli, ChiaraMarra, AntonioViale, GiuseppeCurigliano, GiuseppeGuerini Rocco, ElenaCriscitiello, CarmenFusco, Nicola + Article (author) -
Breast Immunology Network: Toward a Multidisciplinary and Integrated Model for Breast Cancer Care in Italy 2025 Curigliano, GiuseppeViale, Giuseppe + Article (author) -
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer 2025 Cursano, GiuliaConcardi, AlbertoFrascarelli, ChiaraMangione, ElisaSantaguida, StefanoTosoni, DanielaPece, SalvatoreMarra, AntonioCriscitiello, CarmenCurigliano, GiuseppeViale, GiuseppeVenetis, KonstantinosRocco, Elena GueriniFusco, Nicola + Article (author) -
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer 2024 Pescia C.Sajjadi E.Cursano G.Venetis K.Guerini-Rocco E.Curigliano G.Viale G.Fusco N. + Article (author) -
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ 2024 Guerini-Rocco, ElenaBellerba, FedericaConcardi, AlbertoVeronesi, PaoloFusco, NicolaViale, GiuseppeLazzeroni, Matteo + Article (author) -
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 2024 Conforti F.Rossi G.Viale G. + Article (author) -
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis 2024 Zattarin E.Rossi G.Viale G.Mantovani A.Conforti F. + Article (author) -
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial 2023 Veronesi, PaoloViale, GiuseppeLazzeroni, MatteoJohansson, Harriet + Article (author) -
TMEM123 a key player in immune surveillance of colorectal cancer 2023 Pesce, ElisaOliveto, StefaniaManara, CristinaBevilacqua, ValeriaDe Camilli, ElisaCassinotti, ElisaBaldari, LudovicaViale, GiuseppeBiffo, StefanoAbrignani, Sergio + Article (author) -
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis 2023 Sajjadi E.Venetis K.Ferrero S.Veronesi P.Viale G.Fusco N.Guerini-Rocco E. + Article (author) -
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 2023 Carmen CriscitielloChiara CortiFrancesco Di MecoGiuseppe VialeGiuseppe Curigliano + Article (author) -
The molecular landscape of breast mucoepidermoid carcinoma 2023 Venetis K.Sajjadi E.Guerini-Rocco E.Viale G.Fusco N. + Article (author) -
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies 2023 Carlo PesciaElena Guerini-RoccoGiuseppe VialeNicola Fusco Article (author) -
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) 2023 Vingiani, AndreaVernieri, ClaudioAgnelli, LucaColleoni, MarcoViale, GiuseppeMagnani, LucaPruneri, Giancarlo + Article (author) -
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles 2022 Sajjadi, ElhamVenetis, KonstantinosBlundo, ConcettaFerrero, StefanoVeronesi, PaoloViale, GiuseppeFusco, NicolaGuerini-Rocco, Elena + Article (author) -
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 2022 Viale G. + Article (author) -
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one- carbon metabolism in breast cancer 2022 Filippone, M. G.Bonfanti, R.Tucci, F. A.Montani, F.Freddi, S.Taglialatela, A.Romanenghi, M.Vago, G.Viale, G.Di Fiore, P. P.Minucci, S.Veronesi, P.Tosoni, D.Pece, S. + Article (author) -
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis 2022 Viale, Giuseppe + Article (author) -